Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blanke

Showing results (121-130 of 190) with videos related to

Pageof 19
Sort By:
Clinical Colorectal Cancer|December 14, 2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713Cynthia Gail Leichman, Shannon L McDonough, Stephen R Smalley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trialM A Gordon, H M Gundacker, J Benedetti, et al.
Journal of the National Cancer Institute|August 30, 2024
Plant-based diet and survival among patients with metastatic colorectal cancerEn Cheng, Fang-Shu Ou, Clare Gatten, et al.
Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke, George D Demetri, Margaret von Mehren, et al.
Archives of Pathology & Laboratory Medicine|February 4, 2010
Protocol for the examination of specimens from patients with gastrointestinal stromal tumorBrian P Rubin, Charles D Blanke, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2026
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare CancersS P Patel, M Othus, Y K Chae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2024
<i>HER2</i> Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405Francesca Battaglin, Fang-Shu Ou, Xueping Qu, et al.
Journal of the American College of Surgeons|June 26, 2012
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrenceMartin D McCarter, Cristina R Antonescu, Karla V Ballman, et al.
Pageof 19

Showing results (121-130 of 190) with videos related to

Sort By:
Pageof 19
Clinical Colorectal Cancer|December 14, 2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713Cynthia Gail Leichman, Shannon L McDonough, Stephen R Smalley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trialM A Gordon, H M Gundacker, J Benedetti, et al.
Journal of the National Cancer Institute|August 30, 2024
Plant-based diet and survival among patients with metastatic colorectal cancerEn Cheng, Fang-Shu Ou, Clare Gatten, et al.
Cancer Epidemiology|June 25, 2018
The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trialsJoseph M Unger, William E Barlow, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke, George D Demetri, Margaret von Mehren, et al.
Archives of Pathology & Laboratory Medicine|February 4, 2010
Protocol for the examination of specimens from patients with gastrointestinal stromal tumorBrian P Rubin, Charles D Blanke, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2026
DART (NCI/SWOG S1609): Comprehensive Final Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare CancersS P Patel, M Othus, Y K Chae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2024
<i>HER2</i> Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405Francesca Battaglin, Fang-Shu Ou, Xueping Qu, et al.
Journal of the American College of Surgeons|June 26, 2012
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrenceMartin D McCarter, Cristina R Antonescu, Karla V Ballman, et al.
Pageof 19